Fexofenadine Hydrochloride Tablets, 180 mg recall — Sun Pharmaceutical Industries Inc (Class III)
Sun Pharmaceutical Industries Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Fexofenadine Hydrochloride Tablets, 180 mg — a Class III recall, initiated 2026-06-01 and posted to the FDA enforcement report on 2026-07-08, under recall number D-0654-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications”. From the product description, the form is tablets, the strength given is 180 mg and the package is described as 150 Tablets. 1 National Drug Code number is printed in the record: 66336-561-30. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99110. Sun Pharmaceutical Industries Inc accounts for 6 recall records in the indexed dataset. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0654-2026 |
|---|---|
| FDA event ID | 99110 |
| Classification | Class III (least serious regulatory tier) |
| Status | Ongoing |
| Recalling firm | Sun Pharmaceutical Industries Inc |
| Recall initiated | 2026-06-01 |
| Reported by FDA | 2026-07-08 |
| Report lag | 37 days from initiation to report |
| Distribution | U.S. Nationwide — Nationwide (US) |
| Firm location on record | NJ, United States |
| Product description (source) | Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distributed by: Ohm Laboratories, Inc., New Brunswick, NJ 08901. NDC 66336-561-30 |
Reason reported by FDA
Failed Impurities/Degradation Specifications
3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
5 identifying values matched by exact pattern in the 22-word product description above; each is a literal substring of it.
| Product named | Fexofenadine Hydrochloride Tablets |
|---|---|
| Form | Tablets |
| Strength | 180 mg |
| Package | 150 Tablets |
| NDC | 66336-561-30 |
| Distributed by | Ohm Laboratories, Inc. |
Other indexed recalls from Sun Pharmaceutical Industries Inc
6 indexed records name Sun Pharmaceutical Industries Inc as the recalling firm, across 5 FDA events, reported 2026-06-10 to 2026-07-08. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Perampanel CIII Tablets, 6mg | D-0628-2026 | Class II | 6mg · Tablets | 2026-07-01 |
| DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL | D-0580-2026 | Class I | 50 mg/25 mL · Injection | 2026-06-17 |
| Budesonide Inhalation Suspension, 1mg/2mL | D-0607-2026 | Class II | 1mg/2mL · Suspension | 2026-06-17 |
| Xyvona (levorphanol tartrate tablets), 2mg | D-0598-2026 | Class II | 2mg · Tablets | 2026-06-10 |
| Xyvona (levorphanol tartrate tablets), 3mg | D-0599-2026 | Class II | 3mg · Tablets | 2026-06-10 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 4 are the Class III ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL | D-0619-2026 | Ani Pharmaceuticals, Inc. | Class III | 2026-07-01 |
| Lidolog Kit, 2% | D-0713-2026 | Asclemed Usa Inc. | Class III | 2026-07-29 |
| Dabigatran etexilate Capsules, 110 mg | D-0735-2026 | Ascend Laboratories, LLC | Class III | 2026-07-29 |
| Dabigatran etexilate Capsules, 150 mg | D-0736-2026 | Ascend Laboratories, LLC | Class III | 2026-07-29 |
Nearest Class III recalls by date
25 of 250 indexed records share the Class III tier; the 7 nearest to 2026-07-08 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Focalin XR (dexmethylphenidate HCl) 5 mg | D-0608-2026 | Sandoz Inc | 5 mg · Extended-Release Capsules | 2026-06-24 |
| Epinephrine Injection, 1mg/mL | D-0581-2026 | Fresenius Kabi Usa, LLC | 1mg/mL · Injection | 2026-06-17 |
| Primidone Tablets, 50 mg | D-0585-2026 | Amneal Pharmaceuticals, LLC | 50 mg · Tablets | 2026-06-17 |
| Lidocaine HCl Injection, 2% | D-0552-2026 | Eugia US LLC | 2% · Injection | 2026-06-10 |
| Dabigatran Etexilate Capsules, 150 mg | D-0737-2026 | Ascend Laboratories, LLC | 150 mg · Capsules | 2026-08-05 |
| Dabigatran Etexilate Capsules, 75 mg | D-0738-2026 | Ascend Laboratories, LLC | 75 mg · Capsules | 2026-08-05 |
| Dabigatran Etexilate Capsules, 75 mg | D-0739-2026 | Ascend Laboratories, LLC | 75 mg · Capsules | 2026-08-05 |
Reading this record
Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 66336-561-30 at the FDA source to confirm it is covered.
Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Sun Pharmaceutical Industries Inc (6 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0654-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0654-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-08
- Ingested
- 2026-08-22
- Record hash
0d34895c050bde9f
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.